CONSUMER NEWS    RECALLS    COMPLAINT FORM    SCAM ALERTS  


Complain about a product or service

Small Claims Guide | Class Actions | Lemon Law | FAQ | Resources | Newsletters | Spanish
Automotive    Education    Electronics    Family    Finance    Health    Homeowners    Shopping    Travel   
NEWS   Latest |  Archives |  Auto |  Cells, etc. |  Computers |  Financial |  Health |  Homeowners |  Parents |  Privacy |  Scams |  Seniors |  Travel

FDA Orders New Warning For Avandia

Agency toughens warning about potential risk of heart attack





November 15, 2007

Diabetes
Studies Find Link Between Diabetes and Alzheimer's
Avandia Maker Failed To Report Required Data
Prediabetes: What You Should Know
Study: Large-Breasted Women More Diabetes-Prone
U.S. Diet Dishes Up Diabetes
Weight-Loss Surgery Seen Beneficial to Diabetics
Lack of Deep Sleep May Increase Diabetes Risk
Study: Avandia May Do More Harm than Good
FDA Orders New Warning For Avandia
U.S. Kidney Disease on the Rise
Fish Oil May Fight Diabetes
Avandia vs. Actos: A Doctor's Advice
Avandia Linked to 42% Greater Risk of Heart Attack
Soft Drink Sweetener Linked to Diabetes in Kids
Diabetes Drugs to Get 'Black Box' Warnings
FDA Rejects Advice to Pull Avandia From Market
FDA Advised to Pull Avandia From Market
Avandia, Other Diabetes Drugs Increase Risk of Heart Failure
Dairy Products May Protect Against Metabolic Syndrome
Portion-Control Dishes May Help Obese Diabetics
FDA Issues Safety Alert on Diabetes Drug Avandia
Stem Cell Treatment May "Cure" Diabetes
Diabetes Risk May Be In The Genes
Holiday Gluttony Can Spell Disaster for Undiagnosed Diabetics
Malaria Drug May Fight Common Cause of Diabetes, Heart Disease
Feds Attack Fake Diabetes Cures
FDA Approves New Treatment for Diabetes
Feds Warn Of Counterfeit Diabetes Tests
Study: Weightlifting Helps Overweight Teens Avoid Diabetes
Researchers Say They Can Reverse Type 1 Diabetes
Study: Obesity Major Factor in Diabetes Epidemic
Too Much, Too Little Sleep Linked To Diabetes In Men
Procedure Cures Some Diabetic Mice
Ethnicity Skews Diabetes' Effect on Heart
Pig Cells May Be Useful in Diabetes Treatment
Protein Triggers Fat-Saturated Cell Death
FDA Approves Diabetes Inhaler Exubera
FDA Panel Greenlights Diabetes Inhaler
Breastfeeding May Decrease Diabetes Risk
Low-Fat Dairy Products May Lower Diabetes Risk in Men
Scientists Find Diabetes "Switch"
New Diabetes Treatment Approved
Knowledge of Diabetes Doesn't Always Affect Outcomes
Moderate Exercise Helpful to Diabetes-Prone Women
Life Expectancy Increases; Diabetes Epidemic Worsens

GlaxoSmithKlein, maker of the diabetes drug Avadia, has agreed to add new information to the existing boxed warning in the drug's labeling about potential increased risk for heart attacks.

The U.S. Food and Drug Administration says people with type 2 diabetes who have underlying heart disease or who are at high risk of heart attack should talk with their doctor about the revised warning as they evaluate treatment options. FDA advises doctors to closely monitor patients who take Avandia for cardiovascular risks.

"FDA has moved expeditiously to review the cardiovascular risks of this drug so that we could inform patients and doctors at the earliest possible time of our findings," said Janet Woodcock, M.D., FDA's deputy commissioner for scientific and medical programs, chief medical officer, and acting director of the Center for Drug Evaluation and Research.

Avandia, designed to treat type-2 diabetes, was approved in 1999 as an adjunct to diet and exercise to improve control of blood sugar levels. Avandia is approved to be used as a single therapy or used in combination with metformin and sulfonylureas, other oral anti-diabetes treatments.

During the past year, FDA said it has carefully weighed several complex sources of data, some which show conflicting results, related to the risk of chest pain, heart attacks and heart-related deaths, and deaths from any cause in patients treated with Avandia.

“At this time, FDA has concluded that there isn't enough evidence to indicate that the risks of heart attacks or death are different between Avandia and some other oral type 2 diabetes treatments,” the agency said in a statement.

“Therefore, FDA has requested that GSK conduct a new long-term study to evaluate the potential cardiovascular risk of Avandia, compared to an active control agent. GSK has agreed to conduct the study and FDA will ensure it is initiated promptly.”

The revision of Avandia's existing boxed warning – FDA's strongest form of warning – includes the following statement:

A meta-analysis of 42 clinical studies (mean duration 6 months; 14,237 total patients), most of which compared Avandia to placebo, showed Avandia to be associated with an increased risk of myocardial ischemic events such as angina or myocardial infarction. Three other studies (mean duration 41 months; 14,067 patients), comparing Avandia to some other approved oral antidiabetic agents or placebo, have not confirmed or excluded this risk. In their entirety, the available data on the risk of myocardial ischemia are inconclusive.

The previous upgraded warning, added to certain diabetes drugs (in class of drugs related to Avandia) on Aug. 14, 2007, emphasized that these types of drugs may worsen heart failure, a condition in which the heart does not adequately pump blood, in some patients. GSK is also developing a Medication Guide for patients to provide additional information about the benefits and risks and safe use of Avandia.

To date, no oral anti-diabetes drug has been conclusively shown to reduce cardiovascular risk. Consequently, the agency also will be requesting that labeling of all approved oral anti-diabetes drugs contain language describing the lack of data showing this benefit.



Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.


Consumer News

May 17 2008

Recent Recalls & Safety Alerts

READER SERVICES

Print, Email & More

Subscribe

Free consumer newsletters
Sign up now!





Back to the top |

Advertisement


Home | Rogues Gallery | Good Guys | Complaint Form | News | Recalls | Search | Video | FAQ |
Consumer Resources | Small Claims Guide | Lemon Law | Newsletter | Contact Us
Advertise With Us | Testimonials | Newsroom | RSS Feeds | Radio | Job Postings




Terms of Use Your use of this site constitutes acceptance of the Terms of Use

Advertisements on this site are placed and controlled by outside advertising networks. ConsumerAffairs.com does not evaluate or endorse the products and services advertised. See the FAQ for more information.

Company Response Welcome If complaints about your company appear on our site, we welcome your response. Please see the Response Form for more information.

For more information, see the FAQ and privacy policy. The information on this Web site is general in nature and is not intended as a substitute for competent legal advice.  ConsumerAffairs.com Inc. makes no representation as to the accuracy of the information herein provided and assumes no liability for any damages or loss arising from the use thereof. 

Copyright © 2003-2008 ConsumerAffairs.com Inc.  All Rights Reserved.